Baseline Characteristics and Disease Phenotype in Inflammatory Bowel Disease

Abstract

Copyright © ESPGHAN and NASPGHAN. All rights reserved. AbstractBackground and Aims: Predicting short-term relapses and long-term prognosis is of outmost

A rising incidence and poorer male outcomes characterise early onset paediatric inflammatory bowel disease

“…This underscores the need for better predictive markers of milder disease course in early onset IBD and the relevance of the risk factors identified in this study, including male gender. In addition, similar to data published by Müller et al., a PCDAI >30 at diagnosis was associated with the use of immunomodulators at 1 year . Interestingly, they also reported that initial PUCAI was not indicative of future immunomodulator use.…”

Biochemical Markers, Genotype, and Inflammation in Pediatric Inflammatory Bowel Disease: A Danish Population-Based Study

“…The reason for this difference could be related to difference in design (population based vs. tertiary center) and size of cohort. In the study by Muller et al [18], 44% of their CD cohort had upper GI involvement compared to 28% of our cohort, this could explain the higher inflammatory burden in their tertiary cohort compared to our population-based cohort. They did not report changes in albumin level in their study.…”

“…In our study, we have shown that low albumin in the total CD group was associated with more intensive medical treatment and an increased risk of surgery. The usefulness of biochemical markers in predicting disease course has been addressed in only a few pediatric studies [18,19]. Muller et al [18] looked at CRP, platelet counts, iron, and hematocrit and found that higher CRP was associated with ileal and upper GI involvement in pediatric CD patients at diagnosis.…”

“…The usefulness of biochemical markers in predicting disease course has been addressed in only a few pediatric studies [18,19]. Muller et al [18] looked at CRP, platelet counts, iron, and hematocrit and found that higher CRP was associated with ileal and upper GI involvement in pediatric CD patients at diagnosis. Furthermore, patients with CD and a stricture and/or penetrating phenotype (B2 and B3) had higher CRP.…”

Long-term outcome of immunomodulator use in pediatric patients with inflammatory bowel disease

“…The BELCRO cohort showed that the use of anti-tumor necrosis factor (TNF) agents was associated with older age and colonic disease at diagnosis in children with CD [16]. The Hungarian cohort demonstrated that higher Creactive protein (CRP) at diagnosis was associated with the need for immunomodulators in pediatric IBD patients and a higher Pediatric Crohn's Disease Activity Index (PCDAI) was considered a second risk factor for children with CD [17]. The Porto IBD group, showed that achieving a steroid-free clinical remission with a normal CRP at week 12 was associated with a higher likelihood to be in steroid-free remission by week 52 [18].…”